.

follow-on-google-news

ional Investors’ selling spree has slowed down in the past two weeks and has turned positive over the last five days. FIIs injected around Rs 19,000 Crore during this period, which was mostly due to improved valuations of the Indian market after its steep correction. Additionally, factors such as a strengthening rupee and easing inflation have contributed to a more favourable economic outlook that helped in regaining the confidence among foreign investors. 

Here is a list of Companies in which the FII has purchased shares through Block deals

Integrated Core Strategies (Asia) Pte Ltd has purchased shares worth around Rs 186 Crore in three different companies. 

Federal Bank Ltd 

The shares of Federal Bank Ltd, with a total market capitalization of Rs 47,536.05 Crore on Wednesday, reached an Intraday high at Rs 196.5 per share, gaining around 0.85 percent in the morning trading session. However, as of 11:00 am, the shares were trading on a flatter trend at Rs 195 per share as against the previous closing price of Rs 194.85. 

On March 25 2025, Integrated Core Strategies (Asia) Pte Ltd purchased 9,80,453 shares of Federal Bank Ltd at an average price of Rs 195.80 per share from UBS AG.  

Federal Bank Ltd is a leading private-sector bank in India, offering a wide range of banking products and services, including retail, corporate, and SME banking. With a strong presence across India, the bank focuses on delivering innovative financial solutions and customer-centric services. It has a robust digital banking platform, ensuring accessibility and convenience for customers. 

Glenmark Pharmaceuticals Ltd 

The shares of Glenmark Pharmaceuticals Ltd, with a total market capitalization of Rs 41,437.92 Crore on Wednesday, reached an Intraday high at Rs 1,489.75 per share, gaining around 0.61 percent in the morning trading session. However, as of 11:00 am, the shares were trading at Rs 1,475, which was 0.4 percent lower than the previous closing price of Rs 1480.75. 

On March 25 2025, Integrated Core Strategies (Asia) Pte Ltd acquired 2,64,465 shares of Glenmark Pharmaceuticals Ltd at an average price of Rs 1,492.65 per share from UBS AG.  

Glenmark Pharmaceuticals is an Indian multinational pharmaceutical company that operates in over 80 countries and has a strong international presence, with 14 manufacturing facilities and 4 R&D centers worldwide. The company focuses on innovative medicines in oncology, dermatology, and respiratory therapy areas. It also has a strong presence in other therapeutic areas like diabetes, cardiovascular diseases, and oral contraceptives. 

Max Financial Services Ltd 

The shares of Max Financial Services Ltd, with a total market capitalization of Rs 38,809.88 Crore on Wednesday, opened and hit an Intraday high at Rs 1,144 per share, gaining around 0.5 percent in the morning trading session. However, as of 11:00 am, the shares were trading at Rs 1,119 per share, which was 1.7 percent lower than the previous closing price of Rs 1480.75. 

On March 25 2025, Integrated Core Strategies (Asia) Pte Ltd bought 11,00,123 shares of Max Financial Services Ltd at an average price of Rs 1,157.35 per share from UBS AG.  Written by

Max Financial Services Limited is the parent company of Max Life Insurance, a leading private life insurer in India. The company offers a range of life insurance solutions, including term insurance, savings, and investment plans, through a multi-channel distribution network. Its investor base includes global financial institutions like KKR, Ward Ferry, Vanguard, Blackrock, Jupiter, Dimension, Norges, and more. 

Written by Adhvaitha Nayani

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

×